stockrow
Saturday 7 November 2026
Export ORIC’s income statement to Excel — free account
Oric Pharmaceuticals, Inc.
ORIC Healthcare Biotechnology
- EPS
- +19.2%
- Free cash flow
- −3.42%
Quarter to June 2026, against a year earlier
8.80
0.31
+3.65%
Follow ORIC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 3 | 3 | 3 | 0.0% | |
| Gross margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | (22) | (21) | (27) | (74) | (79) | (89) | (101) | (128) | (129) | (140) | +24.8% | ||||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (21) | (27) | (74) | (79) | (89) | (101) | (128) | (129) | (140) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | (0.74) | (12.32) | (14.16) | (3.36) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) | (1.35) | +9.0% | ||||||
| Cash flow | — | (0.70) | (11.93) | (12.39) | (2.06) | (1.57) | (1.89) | (1.67) | (1.62) | (1.26) | (1.03) | +7.7% | ||||||
| Capex | — | 0.00 | (0.30) | (0.40) | (0.03) | (0.02) | (0.05) | (0.02) | (0.02) | (0.01) | (0.01) | n/m | ||||||
| Free cash flow | — | (0.70) | (12.23) | (12.80) | (2.09) | (1.59) | (1.95) | (1.68) | (1.63) | (1.27) | (1.04) | +7.8% | ||||||
| Book value | — | 0.86 | 0.00 | (47.44) | 13.21 | 7.19 | 5.61 | 4.36 | 3.49 | 4.38 | 3.53 | +22.6% | ||||||
| Shares, m | — | 30 | 2 | 2 | 22 | 38 | 40 | 51 | 70 | 88 | 100 | +14.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | (21) | (21) | (24) | (45) | (60) | (75) | (86) | (113) | (111) | (112) | +23.3% | |||||
| Capex | — | 0 | (1) | (1) | (1) | (1) | (2) | (1) | (1) | (1) | (1) | +4.9% | ||||||
| Free cash flow | — | (21) | (21) | (24) | (46) | (60) | (77) | (87) | (114) | (112) | (112) | +23.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 24 | 41 | 85 | 288 | 225 | 195 | 192 | 237 | 268 | 253 | +35.2% | |||||
| Net debt | — | (26) | (43) | (89) | (294) | (237) | (206) | (208) | (256) | (281) | (265) | +34.8% | ||||||
| Shareholders’ equity | — | 26 | — | (90) | 290 | 273 | 222 | 224 | 243 | 384 | 381 | +40.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | (57.40) | 0.00 | (57.14) | (37.50) | (26.34) | (32.66) | (40.34) | (48.60) | (37.91) | (37.35) | +19.5 pt | |||||
| ROIC | — | 0.00 | 0.00 | 0.00 | 0.00 | (136.94) | (356.70) | (435.43) | 0.00 | (86.88) | (83.77) | (86.9) pt | ||||||
| ROE | — | 40.78 | 39.55 | 34.80 | (73.82) | (27.98) | (35.99) | (45.11) | (54.73) | (41.27) | (39.80) | (82.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 57 | 61 | 78 | 86 | 100 | 115 | 104 | — | +10.5% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Oric Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SVRA Savara Inc. | $899.9M | — (loss-making) | — (loss-making) | — | n/m | −14.05% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| JBIO Jade Biosciences, Inc. | $896.7M | — (loss-making) | — | — | n/m | −115.11% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CTY City Therapeutics, Inc | $882.9M | — | — | — | — | — | — | — | Compare |
| ORIC Oric Pharmaceuticals, Inc. | $880.0M | — (loss-making) | — | — | n/m | −3.42% (below 0%: shrinking) | 0.00% | 0.00% | |
| GLUE Monte Rosa Therapeutics, Inc. | $874.5M | — (loss-making) | — (loss-making) | +325.80% (above 0%: growing) | n/m | −142.63% (below 0%: shrinking) | 100.00% | (3.57%) | Compare |
| PHAR Pharming Group N.V. Sponsored ADR | $870.6M | 34.2× | — (loss-making) | +20.86% (above 0%: growing) | +190.91% (above 0%: growing) | +0.42% (above 0%: growing) | 86.90% | 25.34% | Compare |
| IVA Inventiva S.A. Sponsored ADR | $867.9M | — (loss-making) | — (loss-making) | −10.77% (below 0%: shrinking) | n/m | −20,989.22% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LTGO Latigo Biotherapeutics Inc | $862.6M | — | — | — | n/m | — | — | 0.00% | Compare |
| ANRO Alto Neuroscience, Inc. | $858.2M | — (loss-making) | — | — | n/m | −43.41% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $872.5M | — | — | +20.86% | — | −79.26% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 28 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 5.57m | 5.69m | 88.91 |
| 2024 | 5.28m | 4.27m | 87.72 |
Ownership
Directors and executive officers, together
5.70%
Entities affiliated with Viking Global Investors
9.06%
Entities affiliated with Nextech Crossover LP
6.92%
Entities affiliated with EcoR1 Capital, LLC
6.50%
Entities affiliated with Venrock Healthcare Capital Partners LLC
5.49%
Entities affiliated with BlackRock, Inc.
5.29%
Pfizer Inc.
5.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement